<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874483</url>
  </required_header>
  <id_info>
    <org_study_id>1307.2</org_study_id>
    <secondary_id>2013-000312-21</secondary_id>
    <nct_id>NCT01874483</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 187004
      following multiple dose administration over 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 15 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCt,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)</measure>
    <time_frame>up to 8 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax t,1 (maximum measured concentration of the analyte in plasma after administration of the first dose)</measure>
    <time_frame>up to 8 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 8 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 8 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 187004 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose given over 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 2</description>
    <arm_group_label>BI 187004 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 4</description>
    <arm_group_label>BI 187004 dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 5</description>
    <arm_group_label>BI 187004 dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 6</description>
    <arm_group_label>BI 187004 dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 7</description>
    <arm_group_label>BI 187004 dose 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 1</description>
    <arm_group_label>BI 187004 dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004, dose 3</description>
    <arm_group_label>BI 187004 dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Type 2 diabetes mellitus

          2. Current treatment with no more than one anti-diabetic drug (except for insulin and
             GLP-1 analogues)

          3. Males or post-menopausal or surgically sterilised females

          4. Age from 20 and to 70 years

          5. HbA1c less or equal to 8.5%

          6. BMI 28-40 kg/m2

          7. Subjects must be able to understand an comply with study requirements

        Exclusion criteria:

          1. Any finding in the medical examination (including BP, PR or ECG) deviating from
             normal that the investigator considers to be of not acceptable clinical relevance

          2. Repeated measurement of systolic blood pressure greater than 160 mm Hg or diastolic
             blood pressure greater than 95 mm Hg

          3. Myocardial infarction, stroke or transient ischemic attack within 6 months prior to
             informed consent

          4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia or
             medically treated hypertension

          5. Surgery of the gastrointestinal tract that might affect absorption and elimination of
             the study drug

          6. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             relevant neurological disorders besides polyneuropathy

          7. Chronic or relevant acute infections (e.g. HIV, hepatitis)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1307.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
